Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury

About this trial

This proof of concept trial is enrolling 28 participants with very acute, traumatic thoracic spinal cord injury to test the safety of eletriptan hydrobromide (TZ-161), a repurposed drug originally approved for the treatment of migraines. TZ-161 activates serotonin receptors in the brain and spinal cord, involved in regulation of nerve signals. If included, participants will be randomly assigned to receive either oral administration of the drug once daily for 6 days alongside standard care, or to receive standard care alone. Final testing of safety will be performed after 6 months.